Literature DB >> 21765872

Biological outcome measurements for behavioral interventions in multiple sclerosis.

Anja Fischer1, Christoph Heesen, Stefan M Gold.   

Abstract

Behavioral interventions including exercise, stress management, patient education, psychotherapy and multidisciplinary neurorehabilitation in general are receiving increasing recognition in multiple sclerosis (MS) clinical practice and research. Most scientific evaluations of these approaches have focused on psychosocial outcome measures such as quality of life, fatigue or depression. However, it is becoming increasingly clear that neuropsychiatric symptoms of MS are at least partially mediated by biological processes such as inflammation, neuroendocrine dysfunction or regional brain damage. Thus, successful treatment of these symptoms with behavioral approaches could potentially also affect the underlying biology. Rigidly designed scientific studies are needed to explore the potential of such interventions to affect MS pathology and biological pathways linked to psychological and neuropsychiatric symptoms of MS. Such studies need to carefully select outcome measures on the behavioral level that are likely to be influenced by the specific intervention strategy and should include biomarkers with evidence for an association with the outcome parameter in question. In this overview, we illustrate how biological and psychological outcome parameters can be combined to evaluate behavioral interventions. We focus on two areas of interest as potential targets for behavioral interventions: depression and fatigue.

Entities:  

Keywords:  behavioral interventions; biomarkers; cortisol; cytokines; depression; fatigue; inflammation; magnetic resonance imaging (MRI); multiple sclerosis

Year:  2011        PMID: 21765872      PMCID: PMC3131172          DOI: 10.1177/1756285611405252

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  139 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Managing fatigue: clinical correlates, assessment procedures and therapeutic strategies.

Authors:  Ik Penner; P Calabrese
Journal:  Int MS J       Date:  2010-01

Review 3.  Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke.

Authors:  H Rickards
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-03       Impact factor: 10.154

4.  Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus.

Authors:  J R Seckl; K L Dickson; C Yates; G Fink
Journal:  Brain Res       Date:  1991-10-11       Impact factor: 3.252

5.  Combined treatment with corticosteroids and moclobemide favors normalization of hypothalamo-pituitary-adrenal axis dysregulation in relapsing-remitting multiple sclerosis: a randomized, double blind trial.

Authors:  F Then Bergh; T Kümpfel; A Grasser; R Rupprecht; F Holsboer; C Trenkwalder
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

6.  Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE.

Authors:  Marina O Ziehn; Andrea A Avedisian; Seema Tiwari-Woodruff; Rhonda R Voskuhl
Journal:  Lab Invest       Date:  2010-02-15       Impact factor: 5.662

7.  The role of helplessness as mediator between neurological disability, emotional instability, experienced fatigue and depression in patients with multiple sclerosis.

Authors:  S P van der Werf; A Evers; P J H Jongen; G Bleijenberg
Journal:  Mult Scler       Date:  2003-02       Impact factor: 6.312

8.  Does hypothalamic-pituitary-adrenal axis hypofunction in chronic fatigue syndrome reflect a 'crash' in the stress system?

Authors:  Boudewijn Van Houdenhove; Filip Van Den Eede; Patrick Luyten
Journal:  Med Hypotheses       Date:  2009-02-23       Impact factor: 1.538

9.  Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis.

Authors:  Dimitrios Papadopoulos; Sumayya Dukes; Ryan Patel; Richard Nicholas; Abhilash Vora; Richard Reynolds
Journal:  Brain Pathol       Date:  2008-05-20       Impact factor: 6.508

10.  Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging.

Authors:  Paul E Sijens; Jop P Mostert; Roy Irwan; Jan Hendrik Potze; Matthijs Oudkerk; Jacques De Keyser
Journal:  Psychiatry Res       Date:  2008-12-30       Impact factor: 3.222

View more
  3 in total

Review 1.  Symptom changes in multiple sclerosis following psychological interventions: a systematic review.

Authors:  Francesco Pagnini; Colin M Bosma; Deborah Phillips; Ellen Langer
Journal:  BMC Neurol       Date:  2014-11-30       Impact factor: 2.474

2.  The factor structure of the Center for Epidemiological Study - Depression Scale in people with multiple sclerosis.

Authors:  Ian I Kneebone; Chris Fife-Schaw; Lawrence T Lam; Roshan das Nair
Journal:  F1000Res       Date:  2020-08-25

3.  The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme.

Authors:  Heleen Beckerman; Lyan Jm Blikman; Martin Heine; Arjan Malekzadeh; Charlotte E Teunissen; Johannes Bj Bussmann; Gert Kwakkel; Jetty van Meeteren; Vincent de Groot
Journal:  Trials       Date:  2013-08-12       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.